Download Raphael Catane

yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project

Document related concepts
no text concepts found
Personal Details
Raphael CATANE
Date and place of birth: October 27, 1942,
Roanne, France
Address: (W) Chaim Sheba Medical Center
Tel Hashomer 52621, ISRAEL
Tel: 972-3-5302064
Fax: 972-3-5352214
E-mail:[email protected]
(H) 21 Heller St. Jerusalem 93725
1961-1967 Hebrew University, Hadassah Medical School
Advisor: Prof. Felix Bergman
Title of thesis: Effect of Regitine on blood pressure
Employment History
Director, Division of Oncology, Chaim Sheba Medical Center
Tel Hashomer
Director, Institute of Oncology, Shaare Zedek Medical Center,
Director, Clinical Cancer Research - Pharmaceutical Research
Institute, Bristol-Myers Squibb, Wallingford, CT 06492
Acting Head, Sharett Institute of Oncology, Hadassah University
Hospital, Jerusalem, Israel
Senior physician, Sharett Institute of Oncology, Hadassah University
Hospital, Jerusalem, Israel
Guest Researcher, Biologics Evaluation Section, Investigational Drug
Branch, Cancer Therapy Evaluation Program, National Cancer
Institute, NIH, Bethesda, Maryland
Clinical Associate in the National Cancer Institute, Radiation
June 2004
Oncology Branch, Bethesda, Maryland
Special Assistant to the Chief Investigational Drug Branch, Division
of Cancer Treatment, National Cancer Institute, Bethesda, Maryland
Clinical Associate in Oncology, Roswell Park Memorial Institute,
Buffalo, New York
Fellow in Medical Oncology, Center for Developmental Oncology,
Roswell Park Memorial Institute, Buffalo, New York.
Resident, Department of Internal Medicine, Barzilai Medical Center,
Ashkelon, Israel
Rotating Internship, Hadassah Hospital, Jerusalem, Israel
Professional Activities
Position in academic administration
Associate Professor, Oncology, Hebrew University-Hadassah
Medical School, Jerusalem, Israel (tenured)
Senior Lecturer, Department of Clinical Oncology, Hadassah
University Hospital, Jerusalem, Israel (tenured)
Visiting Associate Professor and Chairman, Division of
Oncology, Tel Hashomer Campus, Tel Aviv University, Israel
Membership in professional/scientific societies
Member – American Society of Clinical Oncology
Member - Israel Society of Clinical Oncology & Radiotherapy
Member - European Association for Cancer Research (EACR)
Member - European Society of Medical Oncology (ESMO)
Member - Israel Society of Immunology
Member - American Association Cancer Research
June 2004
Original Articles
1. Bergman F, Catane R, Korczin AD: Central action of regitine
(phentolamine) on blood pressure. Arch. Intern. Pharmacodyn. 168:
278-287, 1967.
2. Catane R, Kaufman J, West C, Merrin C, Tsukada Y and Murphy GP:
Brain metastasis from prostatic carcinoma. Cancer 38:2583-2587,
3. Catane R, Mittelman A, Kaufman J and Murphy G: Oral estramustine
phosphate. Prolonged therapy for advanced carcinoma of the prostate.
New York State J. of Med. 76:1978-1981, 1976.
4. Catane R, Kaufman J, Mittelman A and Murphy GP: Combined
therapy of
advanced prostatic carcinoma with estramustine and
prednimustine. J. Urol. 117:332-335, 1977.
5. Kaufman JH, Catane R and Douglas HO: Combined adriamycin,
vincristine and methotrexate in advanced adult soft tissue sarcoma.
New York St. J. Med. 77:742-743, 1977.
6. Catane R, Catane H, Takita H, Kaufman J, Mittleman A and Murphy
Preliminary study of prednimustine in lung cancer. J. Med.
8:115-121, 1977.
7. Mittelman A, Catane R and Murphy GP: New steroidal alkylating
agents in
the treatment of advanced, stage D, carcinoma of the
prostate. Cancer Treat. Rep. 61:307-310, 1977.
8. Catane R, Kaufman J, Bakshi S, Parthasarathy KL, Mittelman A and
Murphy GP: Bone marrow scanning in advanced prostatic carcinoma.
New York St. J. Med. 77:1413-1416, 1977.
9. Catane R, Wajsman Z, Chu TM, Saroff J, Mittelman A and Murphy
GP: Simultaneous measurement of acid phosphatase activity in bone
marrow and peripheral blood serum. Surgical Forum, 28:128-130,
10. Didolkar MS, Baffi RR, Catane R, Kaufman J and Holyoke ED: Use of
methyhl CCNU and procarbazine in advanced malignant melanoma
resistant to DTIC therapy. Cancer Treat. Rep., 61:1738-1739, 1977.
11. Mittelman A, Catane R and Murphy GP: Clinical experience with
estramustine phosphate (Estracyt) in hormonally resistant stage D
carcinoma of the prostate. Current Chemotherapy 2:1278-1282, 1977.
June 2004
12. Catane R, Kaufman J, Madajewicz S, Mittelman A and Murphy GP:
Prednimustine therapy for advanced prostatic cancer: Brit. J. Urol.
50:29-32, 1978.
13. Catane R, Bono VH, Jr., Louie AC and Muggia FM: High dose
methotrexate not a conventional treatment. Cancer Treat. Rep. 62:178180, 1978.
14. Rozencweig M, Von Hoff DD, Catane R and Muggia FM: Platinum
Chemotherapy,23:99-112, 1978.
15. Catane R: Clinical experience with estramustine phosphate and
prednimustine: Two steroidal alkylating agents compound. Cancer
Treat. Rep. 62:1264-1265, 1978.
16. Catane R, Lev L and Rozencweig M: Cis-Diamminedichloroplatinum
(DDP). A new drug for cancer. Harefuah 92: 420-430, 1978 (Hebrew).
17. Catane R, Madajewicz S, Wajsman Z, Chu TM and Mittelman A:
Prostatic cancer, immunochemical detection of prostatic acid
phosphatase in serum and bone marrow. New York St. J. Med.,
78:1060-1061, 1978.
18. Catane R, Kaufman J, Nime F, Evans JT and Mittleman A: Phase I
study of N6 Benzyladenosine 5'Monophosphate. Cancer Treat. Rep.
19. Catane R and Catane H: High dose methotrexate for the therapy of
malignant diseases. Harefuah, 95:225-226, 1978. (Hebrew).
20. Penta JS, Von Hoff DD, Louie A, Catane R, Rozencweig M and
Drug-related fatalities following methotrexate and
citrovorum factor administration. Chemiotherapia Oncologica, 2:170174, 1978.
21. Catane R, Louie A and Penta J: Analysis of protocols with high dose
methotrexate sponsored by DCT/NCI. Chemiotherapia Oncologica 2:
209-220, 1978.
22. Catane R, Von Hoff DD, Glaubiger D and Muggia FM: Azaserine,
DON and azotomycin, three diazo analogs of L-glutamine with clinical
antitumor activity. Cancer Treat. Rep. 63:1033-1138, 1979.
23. Muggia FM, Catane R, Douros J and Cooney D: Amino acid
manipulations in cancer treatment. A perspective from the NCI
workshop. Cancer. Treat. Rep. 63:1137, 1979.
June 2004
24. Ovejera AA, Houchens DP, Catane R, Sheridan MA and Muggia FM:
Efficacy of 6-diazo-5-oxo-L-norleucine and N-(N-gamma-Glutamyl 6-diazo5-oxo-L-norleucine)-6-diazo-5-oxo-L-norleucine
tumors in conventional and nude mice. Cancer Res. 39:3220-3224, 1979.
25. Lee YJ, Catane R, Rozencweig M, Bono VH, Jr., Muggia FM, Simon R and
Staquet M: Analysis and interpretation of response rate for anticancer drugs.
Cancer Treat. Rep. 63:1713-1720, 1979.
26. Lee YJ, Staquet M, Simon R, Catane R and Muggia FM: Two stage plans for
patient accrual in Phase II cancer clinical trials. Cancer Treat. Rep. 63: 17211726, 1979.
27. Catane R, Mittelman A, Murphy GP and Sandberg AA: Effects of
testosterone on estracyt localization in rat prostate. Oncology 37:357-359,
28. Karakousis CP, Lopez R, Catane R, Rao V, Moore R and Holyoke ED:
Intraarterial adriamycin in the treatment of soft tissue sarcomas. J. of Surg.
Oncol. 13:21-27, 1980.
29. Madajewicz S, Catane R, Mittelman A, Wajsman Z and Murphy GP:
Chemotherapy of advanced, hormonally resistant, prostatic carcinoma.
Oncology 37:53-56, 1980.
30. Kisner DL, Catane R and Muggia FM: The rediscovery of DON
(6-diazo-5-oxo-L-Norleucine). Recent Results Cancer Res. 74:258-263,
31. Clement JJ, Gorman MS, Wodinsky I, Catane R and Johnson RK:
Enhancement of antitumor activity of alkylating agents by the radiation
sensitizer misonidazole. Cancer Res. 40:4165-4172, 1980.
32. Catane R and Muggia FM: Electron-affinic radiosensitizers: Development
and clinical prospects. Applied Radiol. 10:25-32, 1981.
33. Halpern J, Catane R, Biran S and Fuks Z: DTIC and actinomycin D with and
without C. parvum immunotherapy in advanced malignant melanoma.
Tumori 67:215-217, 1981.
34. Witliff J and Catane R: Screening techniques and clinical studies. In Raus
J.: Cytotoxic Estrogens. J. Toxicol Environ Health 7:164-165, 1981.
35. Catane R, Schwade JG, Yaar I, Lichter AS, Tepper JE, Dunnick NR, Brody
L, Brereton H, Cohen M and Glatstein E: Follow-up neurological evaluation
in patients with small cell lung carcinoma treated with prophylactic cranial
June 2004
irradiation and chemotherapy. Int. J. Radiation Oncol. Biol. Phys. 7:105-109,
36. Sulkes A, Catane R and Fuks Z: Predictive tests for cancer chemotherapy.
Harefuah 100:249-250, 1981 (in Hebrew).
37. Muggia FM, Penta JS, Catane R, Jensen-Akula MS and Charles LM:
Selected anticancer drugs in Phase I trials in the United States. Recent
Results Cancer Res. 76:192-209, 1981.
38. Catane R, Lichter A, Lee YJ, Brereton HD, Schwade JG and Glatstein E:
Small cell lung cancer: Analysis of treatment factors contributing to
prolonged survival. Cancer 48:1936-1943, 1981.
39. Poster DS, Bruno S, Penta JS, Pina K and Catane R: Current status of
chemotherapy in the treatment of advanced carcinoma of the thyroid gland.
Cancer Clinical Trials 4:301-307, 1981.
40. Carol J, Fuks Z, Catane R, Fridkin M and Treves AJ: The effect of tuftsin
on human monocyte cytotoxicity. J. Immun. Resp. Mod. 1:1982.
41. Siegal T, Pfeffer RM, Catane R, Gomori MJ, Sulkes A and Fuks Z:
Successful chemotherapy of recurrent intracranial germinoma with spinal
metastases. Neurology 35:631-633, 1983.
42. Halpern J, Catane R, Sacks T and Fuks Z: Treatment of febrile
granulocytopenic cancer patients receiving antineoplastic therapy with a
combination of carbenicillin, cefazolin and gentamycin. J. Medicine 14:
193-203, 1983.
43. Catane R, Schlanger S, Weiss L, Penchas S, Fuks Z, Treves AJ, Gottlieb P
and Fridkin M: Antitumor effect of tuftsin in animals. An. N.Y. Acad. Sci.
419:251-260, 1983.
44. Klin, B., Peretz, T., Catane, R, Olschwang D and Magora F:
morphine analgesia. Harefuah 106:70-71, 1984 (in Hebrew).
45. Brufman G, Halpern J, Sulkes A, Catane R and Biran S: Procarbazine,
CCNU, and vincristine (PVC) combination chemotherapy for brain tumors.
Oncology 41:239-241, 1984.
46. Catane R, Pfeffer MR, Livni N, Rosenmann E, Treves AJ and Eshhar Z:
Monoclonal antibodies to carcinoembryonic antigen (CEA) in primary and
metastatic tumors. Immunology and Hematology Research Monograph 2:
358-361, 1984.
47. Yablonski-Peretz T, Halpern J, Sulkes A, Fuks Z and Catane R: Small cell
lung cancer. Harefuah 106:450-453, 1984 (in Hebrew).
June 2004
48. Halpern J, Catane R and Baerwald H: A call for caution in the use of
aminogluthetimide: Negative reactions with dexamethasone and beta blocker
treatment. J. Medicine 15:59-63, 1984.
49. Pfeffer R, Sulkes A, Peretz T, Fuks Z and Catane R: Phase I study of the
combination of mitomycin-C and oral metronidazole. Cancer Treat. Rep.
68:1191-1192, 1984.
50. Uziely B, Sulkes A, Libson E, Isacson R, Ben-Baruch N, Gez E,
Effrati-Warner E, Biran S, Fridkin M and Catane R: A Phase II study of
tuftsin for the treatment of non-small cell carcinoma of the lung.
Chemioterapia 4:1166-1167, 1985.
51. Halpern J and Catane R: Oral estramustine phosphate (Estracyt): A broad
phase II study. J. Medicine 15:35-43, 1984.
52. Peretz T, Klin B, Warner E, Olschwang D and Catane R: Continuous
epidural narcotic analgesia for intractable pain due to malignancy. J. Surg.
Oncol. 29:8-10, 1985.
53. Gez E, Catane R, Pfau L and Biran S: High dose metoclopramide as an
antiemetic in patients receiving cis-platinum based combination
chemotherapy. Gynecol. Oncol. 21:18-22, 1985.
54. Gez E, Sulkes A, Isacson R, Catane R and Weshler Z.: Radiation
pneumonitis: A Complication resulting from combined radiation and
chemotherapy for early breast cancer. J. Surg. Oncol. 30:116-119, 1985.
55. Siegal T, Siegal TZ, Fields SI, Mizrachi R and Catane R: A selective route of
doxorubicin administration improves outcome in experimental malignant
epidural cord compression. Neurosurgery 8:576-580, 1986.
56. Catane R, Sulkes A, Uziely B, Gez E, Isacson R, Treves AJ and Fridkin M:
Initial clinical studies with tuftsin. Int. J. Immunother. 2:81-85, 1986.
57. Sulkes A, Gez E, Pfeffer R, Catane R, Isacson R and Biran S: Adriamycin,
vinblastine and mitomycin-c (AVM) as second line chemotherapy in
advanced breast cancer. Cancer Chemother. Pharmacol. 18:162-167, 1986.
58. Ben-Yoseph R, Catane R, Libson A, Chisin R, Kaplan N and Atlan H:
Nuclear magnetic resonance in the diagnosis of spinal malignancy. Harefuah
111:39-42, 1986 (in Hebrew).
59. Warner E, Sulkes A, Gez E, Uziely B, Ben-Baruch N, Ben-Yosef R, Biran S
and Catane R: Combined immunotherapy and chemotherapy with tuftsin
cyclophosphamide in the treatment of small cell lung cancer. Chemioterapia
June 2004
6:706- 708, 1987.
60. Siegal T, Sandbank U, Gabizon A, Siegal TZ, Mizrachi R, Ben-David E and
Catane R: Alteration of blood-brain-CSF barrier in experimental meningeal
carcinomatosis: A morphologic and adriamycin-penetration study. Journal
of Neuro-Oncology, 4:233-242, 1987.
Kedar E, Zeira E, Lebendiker Z, Weiss DW, Catane R and Shouval D:
Human and mouse "LAK" cells expanded in long-term cultures: In vitro and
in vivo studies. In: Truit R.L., Gale, R.P. and Bortin, M.M.: Cellular
Immunotherapy of Cancer. Prog. Clin. Biol. Res. 244:59-75, 1987.
Siegal T, Siegal TZ, Sandbank U, Shohami R, Shapira J, Gomori IM,
Ben-David E and Catane R: Experimental neoplastic spinal cord
compression: Evoked potentials, edema, prostaglandins and light and
electron microscopy. Spine 12:440-448, 1987.
Catane R, Catane H and Robinson E: The National Cancer Institute
(U.S.A.)faces controversies. (Editorial). Harefuah 114:308-310, 1988 (in
Catane R and Longo DL: Monoclonal antibodies for cancer therapy. Isr. J.
Med. Sci. 24:471-476, 1988.
Siegal T, Melamed E, Sandbank U and Catane R: Early and delayed
neurotoxicity of mitoxantrone and doxorubicin following subarachhnoid
injection. J. Neurooncol 6:135-140, 1988.
Warner-Efrati E, Sulkes A, Weshler Z, Peretz T, Ben-Yosef R, Catane R
and Biran S: Chemotherapy induction, consolidation radiotherapy and
maintenance alternating chemotherapy in small cell carcinoma of the lung.
Isr. J. Med. Sci. 24:593-8, 1988.
Ben-Yosef R, Pfeffer R, Gez E and Catane R: Management of malignant
pericardial effusion. Harefuah 115:138-41, 1988 (in Hebrew).
Siegal T, Siegal Y, Shapira Y, Sandbank U and Catane R: Indomethacin
and dexamethasone treatment in experimental neoplastic spinal cord
compression: Part 1. Effect on water content and specific gravity.
Neurosurgery 22:328-33, 1988.
Gez E, Ben Yosef R, Catane R, Brufman, G and Biran, S: Chlorpromazine
and dexamethazone versus high-dose metoclopramide and dexamethazone in
patients receiving cancer chemotherapy, particularly cis-platinum:
prospective randomized crossover study. Oncology 46:150-154, 1989.
June 2004
Gabizon A, Peretz T, Sulkes A, Amselem S, Druckman S, Ben-Yosef R,
Ben-Baruch N, Catane R, Biran S and Barenholz Y:
Administration of Doxorubicin-Containing Liposomes in Cancer Patients: A
Phase I Study. Europ. J. Cancer Clin. Oncol. 25:1795-1803, 1989
71. Catane R, Ben-Yosef R, Livni N, Rosenmann E and Eshhar Z:
Monoclonal antibodies against carcino-embryonic antigen discriminate
between CEA Produced by Gastrointestinal Tumors and CEA Produced
by Other Tumors. Nat. Immun. Cell Growth Regul. 9:203-208, 1990.
72. Shani A, Tichler T, Catane R, Gurwith M, Rozenszajn LA, Gezin A,
Levi E, Schlezinger M, Kalechman Y, Michlin H, Shalit F, Engelsman
E, Farbstein H, Farbstein M, Albeck M and Sredni, B: Immunologic
effects of AS101 in the treatment of cancer patients. Nat. Immun. Cell
Growth Regul. 9:182-190, 1990.
73. Korenberg A, Catane R, Peller S, Kaufman S and Fridkin M: Tuftsin
induces thromboplastin-like activity in human mononuclear cells and in
monocytic cell lines. Blood. 76:814-819, 1990.
74. Ben-Yosef R, Glaser B and Catane R: A somatostatin analogue (SMS
201-995) for the treatment of gut neuroendocrine tumors. Harefuah
119: 1517-20, 1990 (in Hebrew).
75. Surkis R, Rubinraut S, Dagan S, Tzehoval E, Fridkin M, Ben-Yosef R
and Catane R: Polytuftsin, a potent precursor for slow release of the
phagocytosis stimulating peptide tuftsin. Int. J. Biochem. 22:193-195,
76. Nitzan DW, Livni N, Marmari Y, Ben-Baruch N, Sela J and Catane R:
The use of monoclonal anti-CEA antibody immunohistochemistry in
detecting the origin of oral cavity metastasis. Int. J. Oral Maxillofac.
Surg. 19:162-164, 1990.
77. Gez E, Strauss N, Catane R, Roisman I and Barak V: The correlation
between tumor response, serum prostatic-specific antigen and prostatic
acid phosphatase in prostatic carcinoma patients receiving
hormonetherapy. J. Tumor Marker Oncol 6:45-51, 1991.
78. Krausz Y, Uziely B, Lijovetsky G, Isacson R, Levinger E, Catane R,
Karger H. and Atlan H: Scintigraphic Evaluation of Patients with
Thyroid Carcinoma - Therapeutic Approaches. Isr. J. Med. Sci.
28:206-211, 1992.
79. Drakos PE, Gez E, and Catane R: Hepatitis Due to Cyproterone Acetate.
Eur. J. Cancer 28a:1931-2, 1992.
June 2004
80. Vlodavsky I, Ishai-Michaeli R, Mohsen M, Bar-Shavit R, Catane R,
Ekre H-PT and Svahn CM: Modulation of neovascularization and
metastasis by species of heparin. Advances Exp. Biol. 313:317-327,
81. Krausz Y, Uziely B, Karger H, Isacson R, Catane R and Glaser B:
Recurrence associated mortality in patients with differentiated thyroid
carcinoma. J Surg Oncol 52:164-168, 1993.
82. Haim N, Oman SD, Galai N, Burde B, Nathan S and Catane R:
Estimation of creatinine clearance without 24-hour urine collection: A
useful guide during cisplatin therapy. Acta Oncologica 32:409-412,
83. Gorodetsky R, Mou X, Vexler A, Kaufman B, Catane R and Loewenthal
E: Noninvasive follow-up of platinum pharmacokinetics in the skin of
patients on cisplatin chemotherapy. Cancer, 72:446-454, 1993.
84. Onetto N, Canetta R, Winograd B, Catane R, Dougan M, Grechko J,
Burroughs J and Rozencweig M: Overview of Taxol safety. JNCI,
15:131-140, 1993.
85. Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, Martin
F, Huang A and Barenholz Y: Prolonged circulation time and
enhanced accumulation in malignant exudates of doxorubicin
encapsulated in polyethylene-glycol coated liposomes. Cancer Res,
54:987-992, 1994.
86. Gabizon A, Isacson R, Libson E, Kaufman B, Uziely B, Catane R, BenDor CG, Cass Y, Peretz T, Sulkes A, Chisin R and Barenholz Y:
Clinical studies of liposome-encapsulated anthracyclines.
Oncologica, 33:779-786, 1994.
87. Sredni B, Albeck M, Tichler T, Shani A, Shapira J, Bruderman I, Catane R,
Kaufman B and Kalechman Y: Bone marrow - sparing and prevention of
alopecia by AS101 in non-small-cell lung cancer patients treated with
carboplatin and etoposide. J Clin Oncol, 13:2342-2353, 1995
88. Cherny NJ and Catane R: (Editorial), Professional negligence in the
management of cancer pain. A case for urgent reforms. Cancer, 76:21812185,1995.
89. Marin O, Lernau O and Catane R: Axillary lymph node dissection in breast
90. Cherny N and Catane R: Palliative medicine and the medical oncologist,
defining the purview of care. Hematol/Oncol Clinics N Am, 10:1-20, 1996.
June 2004
91. Sredni B, Xu R-H, Albeck M, Gafter U, Gal R, Shani A, Tichler T, Shapira
Bruderman I, Catane R, Kaufman B, Whisnant JK. The protective role of the
immunomodulatory AS101 against chemotherapy-induced alopecia studies on
Human and animal models. Int J Cancer 65:97-103, 1996.
92. Sredni B, Tichler T, Shani A, Catane R, Kaufman B, Strassmann G, Albeck
M, and Kalechman Y. Predominance of TH1 Response in tumor-bearing
mice and cancer patients treated with AS101. JNCI 88:1276-1284, 1996.
93. Levy-Lahad E, Catane R, Eisenberg S, Kaufman B, Hornreich G, Lishinsky
E, Shohat M, Weber BL, Beller U, Lahad A, Halle D: Founder BRCA1 and
BRCA2 mutations in Ashkenazi Jews in Israel: Frequency and differential
penetrance in ovarian cancer and in breast-ovarian cancer families. Am J
94. Beller U, Halle D, Catane R, Kaufman B, Hornreich G, Levy-Lahad E: High
frequency of BRCA1 and BRCA2 germline mutations in Ashkenazi Jewish
ovarian cancer patients, regardless of family history. Gynecol Oncol 67:123126,
95. Sapir R, Catane R, Strauss-Liviatan N, Cherny NI:
Cancer pain:
Knowledge and attitude of physicians in Israel. J Pain Sympt Manag
96. Chertin B, Spitz IM, Lindenberg T, Kuzman P, Algur N, MooYoung AJ,
Catane R, Farcas A: An implant releasing the GNRH agonist Histerelin
maintains medical castration for up to 30 months in metastatic prostate
97.Levy-Lahad E, Krieger M, Gottfeld T, Renbaum P, Klein G, Eisenberg S,
Lahad A, Kaufman B, Catane R: BRCA1 and BRCA2 mutation carriers as
potential candidates for chemoprevention trials. J Cell Biochem 77:13-18,
98. Sapir R, Catane R, Kaufman B, Isacson R, Segal A, Wein S, Cherny N:
Cancer patient expectations of and communication with oncologists and
oncology nurses: The experience in an integrated oncology and palliative
care service. Support Care Cancer; 8:458-463, 2000.
99. Kalechman Y, Longo DL, Catane R, Shani A, Albeck M, Sredni B:
Synergistic Antitumor Effect of Paclitaxel (Taxol) + AS101 in murine
model of B16 melanoma: association with RAS-dependent signal
transduction pathways. Int J Cancer 86:281-8 , 2000.
100.Sredni B, Longo DL, Catane R, Shani A, Albeck M, Kalechman Y:
Synergistic antitumoral effect of the immunomodulator AS101 +
June 2004
paclitaxel (Taxol). Association with ras-dependent signal transduction
101. Levy-Lahad E, Lahad A, Eisenberg S, Dagan E, Paperna T, Kasinetz L,
Catane R, Kaufman B, Beller U, Renbaum P, Gershoni-Baruch R:A single
nucleotide polymorphism in the RAD51 gene modifies cancer risk in
BRCA2 but not BRCA1 carriers. Proc Natl Acad Sci 98: 3232-3236 , 2001
102. Ron IG, Wigler N, Borovik R, Brufman G, Rizel S, Shani A, Brenner J,
Farbstein H, Dale A, Inbar MJ, Brenner HJ , Chaitchik S, Catane R :
CMF (cyclophosphamide, mitoxantrone, 5-fluorouracil) as adjuvant
chemotherapy for stage II lymph-node positive breast cancer: a phase III
randomized multicenter study. Am J Clin Oncol 24: 323-327 , 2001.
103. Ron IG, Wigler N, Borovik R, Peretz T, Rizel S, Shani A, Brenner J, Farbstein H,
Brenner HJ , Chaitchik S, Catane R, Inbar MJ:
CMF (cyclophosphamide, mitoxantrone, 5-fluorouracil) as adjuvant
chemotherapy for stage II lymph-node positive breast cancer: results by
demographic and clinic subgroups. Am J Clin Oncol 25: 520-2, 2002.
104. Cherny NI, Catane R; European Socity of Medical Oncology Taskforce
on Palliative and Supportive Care: Attitudes of medical oncologists
toward palliative care for patients with advanced and incurable cancer.
Cancer 98(11): 2502-10, 2003.
105. Kohne CH, CataneR, Klein B, Ducreux M, Thuss-Patience P, Niederle N,
Gips M, Preusser P, Knuth A, Clemens M, Bugat R, Figer I, Shani A,
Fages B, Di Betta D, Jacques C, Wilke HJ: Irinotecan is active in
chemonaive patients with metastatic gastric cancer: a phase II multicentric
trail. Br J Cancer 89(6):997-1001, 2003.
106. Cherny NI, Catane R, Kosmidis P; ESMO Taskforce on Supportive and
Palliative Care: ESMO takes a stand on supportive and palliative care.
Ann Oncology 14(9):1335-7, 2003.
107. Yakobson E, Eisenberg S, Isacson R, Halle D, Levy-Lahad E, Catane R,
Safro M, Sobolev V, Huot T, Peters G, Ruiz A, Malvehy J, Puig S,
Chompret A, Avril MF, Shafir R, Peretz H, Bressac-de Paillerets B:
A single Mediterranean, possibly Jewish, origin for the Va159Gly
CDKN2A mutation in four melanoma-prone families: Eur J Hum Genet
11(4):288-96, 2003.
O'Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A,
Catane R, Kieback DG, Tomczak P, Ackland SP, Orlandi F, Mellars L,
Alland L, Tendler C; CAELYX Breast Cancer Study Group: Reduced
cardiotoxicity and comparable efficacy in a phase III trial of pegylated
liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional
June 2004
doxorubicin for first-line treatment of metastatic breast cancer.
Ann Oncol. 15(3):440-9, 2004.
109. Katz D, Segal A, Alberton Y, Jurim O, Reissman P, Catane R, Cherny
NI: Neoadjuvant imatinib for unresectable gastrointestinal stromal tumor.
Anticancer Drugs. 15(6):599-602, 2004.
110. Kundel Y, Pfeffer R, Lauffer M, Ramon J, Catane R, Symon Z: Salvage
prostatic fossa radiation therapy for biochemical failure after radical
prostatectomy: the Sheba experience. Isr Med Assoc J. 6(6):329-31,
Case Reports
1. Catane R, and Davidson JT: A hazard of cuffed flexometallic endotracheal tubes.
Brit. J. Anesthesiol. 41:1086, 1969.
2.Catane R, and Vago T: Puerperal sepsis caused by osteomyelitis of the pubic bone.
Harefuah. 85:370-371, 1973 (in Hebrew).
3.Catane R, and Wisclicki L: Retinal vein thrombosis following intranasal
injection of prednisone. Harefuah. 87:511-512, 1974 (in Hebrew).
4.Catane R, Kaufman JH, Douglas HO, Kim U and Mittelman A: Nephrotic
syndrome associated with gastric cancer. J. Surg. Oncol. 9:207-211, 1977.
5.Catane R, Kaufman J, Mittelman A, and Murphy GP: Disappearance of
osteoblastic metastases in prostatic carcinoma following estramustine
J.A.M.A. 237:2471, 1977 (letter).
6.Catane R, Kaufman J, Mittelman A, and Murphy GP: Attenuation of
myelosuppression with lithium. New Eng. J. Med. 297:452, 1977 (Letter).
7. Litvin Y, Hage S, Catane R and Horne T: Reversibility of glucocorticoid-induced
osteopenia, a case report. Clinical Nuclear Medicine 7:268-271, 1982.
8.Halpern J, Koplovic J and Catane R: Malignant fibrous histiocytoma
developing in irradiated sacral chordoma. Cancer 53:2661-2662, 1984.
9.Yablonsky-Peretz T, Sulkes A, Polliack A, Weshler Z, Okon E and Catane R:
Secondary myelofibrosis with metastatic breast cancer simulating agnogenic
myeloid metaplasia. Report of a case and review of the literature. Med. Pediatr.
Oncol. 13:92-96, 1985.
June 2004
10. Ben-Yosef R, Warner E, Gez E and Catane R: Malignant pericardial effusion
associated with metastatic rectal cancer: Case Report, J. Chemother. 1:342-5,
11. Ben-Yosef R, Gez E and Catane R: Acute pericarditis following bleomycin: a
case report and literature analysis. J. Chemother. 2:70-71, 1990.
12. Drakos P, Bar-Ziv J and Catane R: Tumor lysis syndrome in non-hematologic
malignancies: Report of a case and review of the literature. Am. J. Clin.
Oncol, 17:502-505, 1994.
Review Articles
1. Abell, C., Catane R, Elmer G, Holcenberg J, Roberts J and Wellner D (eds):
Proceedings of the workshop on amino-acid imbalance in the treatment of cancer.
Cancer Treat. Rep. 63:1009-1138, 1979.
2.Catane R, Schwade JG, Turisi AT, Webber BL and Muggia FM: Pulmonary
toxicity after radiation and bleomycin. A review. Int. J. Radiation Oncology
Biol. Phys. 5:1513-1518, 1979.
3.Catane R, Catane H and Robinson E: Small cell lung cancer: Prospects for cure.
Harefuah 27:309-210 1979, (in Hebrew).
4.Catane R, Catane H and Rozencweig M: Economical aspects of cancer therapy.
Harefuah, 128:182-185, 1995 (in Hebrew).
5.Ronson A., Cherny N., Catane R: The Treatment of Pain in Oncology. Med Hyg.
58:1181-1185 , 2000.
Chapters in Books
1. Muggia FM, Catane R, Lee YJ and Rozencweig, M: Factors
Responsible for Therapeutic Success in Osteosarcoma: A Critical
Analysis of Adjuvant Trial Result. In Adj. Therapy of Cancer. Edited
by S.E. Jones and S.E. Salmon. Grune and Stratton, Inc. 1979 pp 383390.
2. Catane R, Bruno S, and Muggia FM: Prospects for Compounds
Utilizing Estrogens as Carriers of Cytotoxic Molecules in Cancer
Treatment. In: Raus J, Martens, H. and Leclerq, C.K.: Cytotoxic
June 2004
Estrogens in Hormone Receptive Tumors.
Press, London, 1980.
pp 263-270, Academic
3. Siegal T, Gabizon A, Sandbank U, Mizrachi R, Siegal TZ, Catane R:
Intravenous Adriamycin in Experimental Meningeal Carcinomatosis:
Tissue Concentrations and Therapeutic Efficacy. In: Biology of Brain
Tumors. Walker M.D., and Thomas D.G. (Eds.), Martinus Nihoff,
Boston, 1986 pp. 445-452.
4. Epstein N, Warner-Efrati E and Catane R: Monoclonal Antibodies in
Cancer Diagnosis and Therapy. In: Mizrachi, A. (ed). Monoclonal
Antibodies Production and Application. Alan R. Liss Inc. 1988, New
York pp. 305-333.
5. Sredni B, Catane R, Shani A, Gezin A, Levi E, Schlezinger M,
Kalechman Y, Michlin H, Shalit F, Rosenzajn LA Farbstein H, and
Albeck M: Phase I study of AS101 (an organotellurium compound) in
patients with advanced malignancies. In: Recent Advances in
Chemotherapy. (Eds.), E. Ruvinstein and D. Adam, Jerusalem, E.
Lewin-Epstein, 1990, pp. 851.1-851.4.
6. Catane R: Cancer of an Unknown Primary Site (CUPS). In:
Everyone's Guide to Cancer Therapy. Edited by M. Dollinger and E.H.
Rosenbaum, Somerville House, Toronto, Andrews and McMeel,
Kansas City & N.Y., 1991, pp. 265-270.
7. Catane R and Mitchell MS: What happens in Biological Therapy. In:
Everyone's Guide to Cancer Therapy. Edited by M. Dollinger and E.H.
Rosenbaum, Sommerville House, Toronto, Andrews and McMeel,
Kansas City & N.Y., 1991, pp. 62-69.
8. Vlodavsky I, Ishai-Michaeli R, Mohsen M, Korner G and Catane R:
Involvement of heparanase and extracellular matrix-bound fibroblast
growth factor in tumor progression. In: Breast Cancer: biological and
clinical progress (ed. L. Dogliotti, A. Sapino and G. Bussolati) Kluwer
Adacemic Publishers 1992 pp. 135-150.
9. Vlodavsky I, Eldor A, Ishai-Michaeli R, Korner G, Benezra M, Catane
R and Bar-Shavit R: Extracellular matrix-bound growth factors,
enzymes and plasma proteins: Possible involvement in atherosclerosis.
Atherosclerosis IX (ed. O. Stein, S. Eisenberg, and Y. Stein) R&L
creative communications Ltd. pp. 351-358, 1993.
10. Vlodavsky I, Benezra M, Ishai-Michaeli R, Catane R and Ben-Sasson
S: Control of tumor-metastasis and angiogenesis by the extracellular
matrix: Involvement of heparan sulfate and heparin-like molecules. In:
Frontiers in Cancer Research, Edited by A. Frensdorff, Tel Aviv
University Edition pp. 188-197, 1993.
June 2004
11. Gabizon A, Uziely B, Kaufman B, Safra T, Catane R and Barenholz Y:
A new generation of doxorubicin-loaded liposomes with improved
localization in tumors: preclinical and clinical studies. In: Cancer
Treatment An Update. Edited by P. Banzet, J.F. Holland, D. Khayat
and M. Weil.
France 1993, pp. 820-822.
12. Kaufman B, Wagschal-Drori L, Gotfeld O, Eisenberg S, Beller U,
Lahad A, Levy-Lahad E, Catane R: Differential clinical and endocrine
features in Ashkenazi ovarian cancer patients with BRCA1 and BRCA2
mutations. In: New Technologies for Gynecologic and Obstetric
Investigation. Edited by A.R. Genozzari and P.G. Artini. CIC
International Edition, Rome, 1999, pp. 55-59.
13. Cherny N.I., Catane R, “Psycho-oncology and Communication,” In:
Cavalli F., Hansen H.H. and Kaye S.B., Textbook of Medical
Oncology, 2nd Ed., London: Martin Dunitz Publishers, 2004 (in press).
Abstracts (since 1992)
1. Kaufman B, Gez E, Feigin E, Wygoda M, Uziely B, Isacson R,
Shnider B, Catane R: Reduction of M-VAC toxicity by Leucovorin.
Proc. Am. Assoc. Cancer Res. 33:219, 1992.
2. Uziely B, Dorembus D, Brufman G, Lewin A, Catane R, Mor-Yosef S:
The effect of tamoxifen on the endometrium. Proc. Am. Assoc. Cancer
Res. 33: 281, 1992.
3. Peretz, T, Kaplan A, Barak V, Baider L, Sulkes A, Rentschler F,
Stephanos S, Catane R: Interferon (IFN) as a modulator of hormonal
therapy in breast cancer. Preliminary results of a randomized study.
Proc. Am. Assoc. Cancer Res. 33:335, 1992.
4. Vexler A, Mou X, Loewental E, Kaufman B, Catane R and Gorodetsky
R: Non-invasive follow-up of platinum level in the skin of patients
during cisplatin therapy. Proc. Am. Assoc. Cancer Res. 33:535, 1992.
5. Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Barenholz Y,
Huang A: Pharmacokinetics of Doxorubicin encapsulated in stealth
liposomes in cancer patients. Annals. Oncol. 3(S1):140, 1992.
6. Sredni B, Albeck M, Bruderman M, Shapiro Y, Tichler T, Shani A,
Catane R, Farbstein M, Kalechman Y: A randomized trial of
chemotherapy versus AS101 plus chemotherapy in patients with nonsmall cell lung cancer Experimental Hematol. 20:778, 1992.
June 2004
7. Brufman G, Uziely B, Gera-Ben-Dor C and Catane, R: Adjuvant
chemotherapy for breast cancer patients with four or more positive
axillary lymph nodes: A preliminary report of a randomized trial
comparing C.M.F. (cyclophosphamide methotrexate and 5-fluorouracil)
versus C.X.F. (cyclophosphamide, mitoxantrone and 5-fluorouracil).
Proc. ASCO 11: 67, 1992.
8. Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Barenholz Y,
Huang A: A pilot study of doxorubicin encapsulated in longcirculating (stealth) liposomes (S-Dox) in cancer patients. Proc. ASCO
11:124, 1992.
9. Peylan-Ramu N, Deutsch V. Heshing Y, Catane R and Eldor A: The
effect of carboplatin (CP) on megakaryocyte (MK) progenitors and
platelet production. Proc. ASCO 11:124, 1992.
10. Tichler T, Bruderman Y, Shani A, Catane R, Brenner H, Kalichman Y,
Farbstein M, Albeck M, Sredni B: Chemotherapy in non-small cell
carcinoma of lung with and without a new immunomodulator - AS101.
Proc. ASCO 11:08, 1992.
11. Onetto N, Rozencweig M, Canetta, R Winograd B, Catane R,
Dougan M, Grechko J, and Burroughs J: An Integrated Analysis of the
Safety of Single Agent Taxol. Proc. 2nd NCI Workshop on Taxol and
Taxus, 1992.
12. Shani A Tichler T, Bruderman I, Shapiro Y, Guber A, Catane, R,
Kalichman, Y, Farbstein M., Albek M, and Sredni B: Granulocytes and
platelets CSF effect of a new immunomodulator. AS101 Annals Oncol
3 (supp 5):8, 1992.
13. Deutsch V, Nagler A, Catane R, Barak V, Slavin S, Olson T and Eldor
A: Megakaryocyte growth factors in sera of thrombocytopenic patients
undergoing chemotherapy, radiotherapy or allogeneic bone marrow
transplantation. Proc. XIVth Congress Internat Soc Thrombosis
Hemostasis, New York, 1993.
14. Lotan C, Peretz T, Lebensart P, Lyass O and Catane R: Tamoxifen
may induce fatty changes in the liver of breast cancer patients. Proc
Am Assoc Cancer Res 34: 200, 1993.
15. Gabizon A, Uziely B, Isacson R, Kaufman B, Safra T, Catane R, and
Barenholz Y: A pilot clinical study of Doxil, a new doxorubicin
liposome preparation. Proc. IVth Internat. Cong. Anti-Cancer
Chemotherapy, Paris, 1993.
16. Fields S, Catane R, Gomori JM, Kaufman B, Tuchner Z, Peretz T,
Libove A and Degani H: Contrast enhanced breast cancer MRI
June 2004
evaluation of chemotherapy response. Breast Cancer Res. & Treat.
27:147, 1993.
17. Tichler T, Shani A, Catane R, Farbstein H, Kalechman Y, Albeck M
and Sredni B: What is MTD? Eur. J. Cancer 29A (Supp 6):535, 1993.
18. Shani A, Tichler T, Pavlozky F, Shapiro Y, Bruderman I, Guber A,
Catane R, Kaufman B, Kalechman Y, Farbstein M, Albeck M and
Sredni B: Platelets, granulocytes and hair growth factor effect of the
new immunomodulator AS101 in chemotherapy treated lung cancer
patients. Eur. J. Cancer 27A (supp 6):552, 1993.
19. Peretz T, Baider L, Catane R, Barak V, Isacson R, Hubert A and
Kaplan A: Interferon and tamoxifen for patients with advanced breast
cancer and negative estrogen receptors. Eur. J. Cancer 27A (supp
6):587, 1993.
20. Pfeffer MR, Sulkes A and Catane R: CADOM (cyclophosphamide,
adriamycin, dacarbazine, vincristine and methotrexate) protocol for
advanced soft tissue sarcomas. Eur. J. Cancer 27 (supp 6):5184, 1993.
21. Catane R, Winograd B, Canetta R, Holcenberg JS, Caron D and
Garrison L: PIXY321: Overview of clinical activity. Proc 2nd
internat. Symposium: Cytokines and Growth Factors in Cancer,
Munich, 1993.
22. Fields S, Degani H, Gomori JM, Libove A, Zajicek G, Peretz T and
Catane R: Magnetic Resonance Imaging of breast cancer allows for
early determination of response to chemotherapy. Proc. Am. Assoc.
Cancer Research 35, 1994.
23. Degani H, Furman E, Margalit R, Horowitz A, Goldberg I, Fields S,
Catane R, Gomori JM, Libove A, Zajicek G and Peretz T: Assessment
of breast cancer response to therapy by contrast enhanced MRI at high
spatial and temporal resolution. Cellular Biochemistry. y-506: 252,
24. Degani H, Fields S, Catane R, Gomori JM, Peretz T and Libove A:
Evaluation of breast cancer therapy with contrast enhanced MRI at high
spatial resolution. JMRI 4:116,1994.
25. Peretz T, Shani A, Borovick R, Steiner M, Catane R, Farbstein A,
Sulkes A and Figer A: A randomized study of 5FU and levamizole vs.
5FU and leucovorin as adjuvant therapy of colon cancer. Proc ASCO,
14:214, 1995.
June 2004
26. Beller U, Ashkenazi J, Hornreich G, Hiller N, Lavie O, Neuman M, and
Catane R: Phase II trial of Paclitaxel in refractory ovarian cancer. Br J
Obst Gynecol 102:342, 1995.
27. Sredni B, Xu R, Tichler T, Shani A, Catane R, Kaufman B, Albeck M,
and Kalechman Y: The protective role of the immuno-modulator AS
101 against chemotherapy-induced alopecia. Proc Am Assoc Cancer
28. Rivenzon D, Polak-Charcon S, Catane R and Degani H: The effect of
retinoic acid on the energetics and glucose metabolism of T47D human
breast cancer cells; NMR studies. Proc Am Assoc Cancer Res
37:A3431, 1996.
29. Sapir R, Catane R and Cherny NI. Cancer pain: Knowledge and
attitudes of physicians in Israel. Proc. ASCO, 16:42, 1997.
30. Kaufman B, Halle D, Catane R, Cherny NI, Isaacson R, Hornreich G,
Beller U and Levy-Lahad E. BRCA Mutation analysis in breast cancer
patients may help prevent subsequent ovarian cancer. Proc. ASCO,
16:537, 1997.
31. Peretz T, Figer A, Borovik R, Steiner M, Catane R, Sulkes A, and Shani
A. 5FU+Leucovorin (LV) as active and less toxic regimen than
5FU+Levamisole (LM) in the adjuvant therapy of colorectal cancer Israel cooperative Oncology group. Proc. ASCO, 16:265, 1997.
32. Catane R, Lahad A, Kaufman B, Isaacson R, Hornreich G, Beller U,
Renbaum P, Halle D, and Levy-Lahad E: BRCA mutations as a
potential tumor diagnostic marker. J Tu Mark Oncol 12:27, 1997.
33. Catane R, Halle D, Kaufman B, Eisenberg S, Isaacson R, Cherny N,
Lahad A, Hornreich G, Beller U, and Levy-Lahad E: Breast and ovarian
cancer risk in BRCA mutation carriers: Implications for prevention.
Eur J Cancer 33:512-513, 1997.
34. Kaufman B, Drori-Wagschall L, Beller U, Lahad A, Isacson R,
Hornreich G, Cherny N, Segal A, Eisenberg S, Halle D, Catane R and
Levy-Lahad E: Differential prognosis and reproductive histories in
Ashkenazi ovarian cancer patients with BRCA1 vs. BRCA2 mutations.
Proc Am Soc Clinical Oncol 17:556A, 1998.
35. Halle D, Catane R, Kaufman B, Isacson R, Cherny N, Beller U,
Hornreich G and Levy-Lahad E: A new BRCA2 mutation in Ashkenazi
and non-Ashkenazi Jewish patients: Another founder mutation? Proc
Am Assoc Cancer Res 39:30, 1998.
June 2004
36. Chertin B, Lindenberg T, Zilberman M, Catane R, Abu-Arafeh W,
Algur N, Kuzma P, Spitz IM and Farkas A: Prolonged testosterone
suppression in prostate cancer with an implant releasing the GnRH
agonist histrelin. Br J Urol 81(S4):69, 1998.
37. Sapir R, Catane R, Kaufman B, Isacson R, Segal A, Wein S, Cherny N:
Cancer patient expectations of, and comunication with oncologists and
oncology nurses: The experience of an integrated oncology and
palliative care service. Proc Am Soc Clin Oncol 18:606a, 1999.
38. Cherny NI, Sapir R, Catane R, Kaufman B, Isacson R, Segal A, Wein S:
Symptom prevalence and severity among ambulatory cancer patients
attending an integrated oncology-palliative care day hospital. Proc Am
Soc Clin Oncol 18:582a, 1999.
39. Fornasiero A, Wormann B, Weh H, Nowacki M, Merimski O, Catane
R, Boussard B, Oulid-Aissa D, Di Costanzi F: Extensive clinical
experience with Campto® within 3 large randomized studies: Data
reported on more than 800 patients (Pts) with metastatic colorectal
cancer (MCRC). Proc Am Soc Clin Oncol 18:284a,1999.
40. Halle D, Renbaum P, Orkin B, Farkash A, Segal A, Cherny N, CataneR:
Substantially improved sensitivity of urine screening for bladder cancer
using genetic markers over routine cytology: Preliminary data from a
prospective study. Proc Am Assoc Ca Res 40:691, 1999.
41. Kohne CH, Thuss-Patience P, Catane R, Klein H, Peretz T, Preusser P,
Niederle N, Ducreux M, Wilke H, Jacques C: Final results of a Phase II
Trial of CPT-11 in patients with advanced gastric cancer. Proc Am Soc
Clin Oncol 18:258a, 1999.
42. Levi-Lahad E, Kaufman B, Eisenberg S, Gottfeld O, Beller U, Renbaum
P, Lahad A, Catane R: Differentiation ovarian cancer survival in
Ashkenazi BRCA1/BRCA2 carriers. Am J Hu Gen 65: A135, 1999.
43. Kaufman B, Segal A, Levi-Lahad E, Eisenberg S, Isacson R, Cherny N,
Beller U, Lahad A, Catane R: Different biological effect of BRCA1 and
BRCA2 mutations in Ashkenazi breast and ovarian cancer patients. Ann
Oncol (Supp 4) 11:21, 2000.
44. Levi-Lahad E, Eisenberg S, Dagan E, , Catane R, Kaufman B, Center P:
The RAD51 –135C SNP modifies breast and ovarian cancer risk in
BRCA2 carriers, but not in BRCA1 carriers. Proc Am Soc Hum Genet ,
45. Cherny NI, Iliam M, Al-Hijawi B, Catane R, Sapir R: Israel, Jordan and
Palestinian Collaborative Cancer Pain Survey. Proc. ASCO 20:300b,
June 2004
46. Goldenberg-Furmanov M, Stein I, Pikarsky E, Catane R, Vigoda M, Laster
M,Corn BW, Ben-Sasson SA: A designer inhibitor of novel protein-kinase
causes regression of human hormone refractory prostate cance xenografts
in nude mice. Europ. J Cancer 37:S218,2001.
47. Yakobson EA, Eisenberg S, Isakson R, Halle D, Levy-Lahad E, Catane R,
Sobolev V, Safro M, Huot T, Peters G, Chompret A, Avril M-F, Shafir R,
Peretz H, Bressac-dePaillerets B: Val 59 Gly CDKN2A (p16) germline
mutation may be of Mediterranean (Jewish?) origin. Melanoma Research
11:S69-S70, 2001
48. Catane R. Defining alternative medicine. Isr Med Assoc J. 4: 314, 2002
49.Catane R, Cherny N, Kaufman B, Portnoy O, Pfeffer R, Sapir R, livneh J, HadasI,
Apter S.: Calcification instead of shrinkage following successful imatinib
therapy Of GIST.Annals of Oncology. 13 (Supp 5): 30-31, 2002.
50. Cherny N, Catane R, Attitudes of ESMO membership to the role of medical
oncologyisis in the palliative care of patients with advanced cancer and dying
patients. Annals of Oncology. 13 (Supp 5): 183, 2002
51. Weitzen R, Zach L, Kaufman B, Tichler T, Rath P, Pfeffer R, Baram J,
Ben-David M, Rizel S, Catane R,: High incidence of brain metastasis (BM)
in patients on trastuzumab for advanced breast cancer: Proc ASCO 21:31b, 2000.
52. Baram J, Goldhammer Y, Ram Z, Tichler T, Nass D, Catane R, Pfeffer R,
Blatt I : Any role for brain irradiation in the treatment of primary central
nervous system lymphoma ( PCNSL). Proc ASCO 21: 67b 2002.
53. Pfeffer MR, Rath P, Kundel Y, Zehavi M, Koller M, Papa M, Shabtai M,
Livne J, Catane R,. A phase I-II study of preoperative radiotherapy and
escalating doses of oral UFT for rectal cancer. Proc ASTRO 2002.
54. Safra T, Simchoni S, Kaufman B, Beller U, Eisenberg-Barzilai
S, Renbaum P, Catane R, Levy-Lahad E,: Moderate breast cancer
penetrance in molecularly proven BRCA 1 / 2 carriers. Proc ASCO
21:427a, 2002.
55. Kundel Y, Catane R, Levitt M, and Pfeffer R: Adjuvant chemotherapy and
whole abdominal irradiation for node positive gastric carcinoma is tolerable
but apparently ineffective: Results of a retrospective analysis.
Gastrointestinal Cancers Symposium, Abstr No. 21, 2004.
56. Wolf I, Sadetzki S, Gluck I, Oberman B, Ben David M, Papa MZ,
Catane R,
Kaufman B: The effects of diabetes mellitus on the diagnosis, stage and
treatment of breast cancer: Proc. ASCO 22:39, (abstr 156), 2003.
June 2004
57. Tichler TE, Wolf I, Brenner H, Catane R:Lack of efficacy of a continuous
infusion, dose intense 5-fluorouracil based combination chemotherapy for the
treatment of carcinoma of unknown primary site.
Proc. ASCO 22:785, (abstr 3155), 2003.
Goldfarb AJ, Bianconi MI, Otero S, Storino C, Abranson D, Soto E,
Catane R, Koliren L:
Multidisciplinary management of gestational
trophoblastic disease (GTD). Proc Asco 22:473 (abstr 1899), 2003.
59. Gluck I, Wolf I, Sadetzki S, Oberman B, Papa MZ, Gluck N, Catane R,
Kaufman B: Prognostic characteristics in very young premenopausal
breast cancer patients compared to older premenopausal patients.
Proc ASCO 22:896 (abstr 3604), 2003.
Gips M, Catane R, Heching I, Levitt l, Segal A, Beb-Shachar M,
Perez T.: The Israeli experience with Gefetinib (`Iressa`, ZD 1839) as single
agent treatment of advanced non-small-cell lung cancer. Proc ASCO 2004.
61. Weber D, Mor K, Catane R, Zymon Z.: Consequences of death on group
process during a long term moderated web based support group.
Proceedings Am Soc Llin Oncol 2004.
62. Weitzen R, Harari G, Catane R, Mandel M.: Melanoma risk in women with
previous breast cancer. Proc ASCO 2004.
June 2004